JP-WXAT@EC2611A

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Increases Holding in Wuxi Biologics H Shares

HSBC Upgrades Wuxi Biologics Rating and Target Price

Goldman Sachs Analyst Gives Buy Rating to WuXi AppTec's H Shares

JPMorgan Raises Target Price for WuXi AppTec to HKD 172

Morgan Stanley Upgrades Rating on Wuxi Biologics Due to Strong Earnings

UBS Raises Goal Price and Earnings Forecast for Wuxi Biologics

WUXI APPTEC released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue HKD 14.1 B (forecast HKD 12.19 B), actual EPS HKD 1.7913 (forecast HKD 1.3856)

WuXi AppTec Reiterates Its 2026 Revenue Guidance

WuXi AppTec Plans to Expand Capacity to Meet Order Demand

WuXi AppTec Reports Strong Core Business Growth in Q1

Company Continues to Focus on and Strengthen CRDMO Business Model

CLSA Raises Revenue and Profit Forecasts for Wuxi Biologics, Maintains Overweight Rating

Citi Raises Target Price on Wuxi Biologics to HKD 158.5

WUXI APPTEC to release FY2026 Q1 earnings on April 27 After-Market BJT, forecast revenue HKD 12.24 B, EPS HKD 1.3914

WuXi AppTec Reports Record Operational Performance in 2025 Annual Report

China Renaissance Maintains Buy Rating on WuXi

JPMorgan Raises 2026-2028 Sales Forecast and Target Price for Wuxi Biologics

WuXi Biologics Reports in Line with Expectations, CLSA Raises Target Price

CICC: Wuxi Biologics Meets Earnings Expectations in 2025

SLING GROUP

GOLDENPOWER

ENTERPRISE DEV

XH NEWS MEDIA

SINO ICT

CONTINENTAL H

NICHE-TECH SEMI

HAO WEN HLDGS

DEEPEXI TECH

ZHOU LIU FU

02359

HSBC Research has raised the target price for WUXI APPTECto HKD162.5 while maintaining a Buy rating. The company reported a YoY revenue growth of 39.4% and a 71.7% increase in adjusted net profit for Q1. The small molecule CDMO business saw an 80.1% YoY surge, exceeding expectations. HSBC also increased its adjusted net profit forecasts for 2026-2028 by 5-6% and anticipates a CAGR of 14.8% in revenue and 17.3% in adjusted net profit from 2025 to 2028.

AASTOCKS News

WUXI APPTEC

HSBC HOLDINGS

HSBC

WuXi AppTec

HSBC 5xShortSG241213

HSBC Holdings Plc

HSBC Research Raises WUXI APPTEC  TP to HKD162.5, Maintains Buy

At today's close, WuXi AppTec's stock price fell sharply by 3.7% to HKD 137.8, after reaching a high of HKD 144.2 during the day and then weakening throughout, ultimately closing in the lowest range of the day. The total trading volume was approximately HKD 1.58 billion, significantly larger compared to recent levels. It is noteworthy that despite the deep single-day decline in stock price, bullish signals have begun to emerge at the daily MACD level, with the convergence of DIF and DEA often indicating that the previously sustained downward momentum is marginally weakening, and the short selling pressure may be entering a phase of release. Although today's high open and low close trend is relatively weak, from a trend cycle perspective, the emergence of this bullish signal is typically regarded as one of the early characteristics of a phase bottom. On the news front, the CXO sector has recently continued to attract market attention. The expectation that the Federal Reserve will remain steady at the April FOMC meeting has basically materialized, and Powell's strong statements have further cooled market expectations for interest rate cuts, putting short-term pressure on global risk appetite. For WuXi AppTec, the rhythm of overseas customer orders and exchange rate fluctuations are the core variables affecting performance. In addition, the Hong Kong stock pharmaceutical sector has recently undergone a round of adjustments, with peers like WuXi Biologics and CanSino Biologics also showing weak performance, creating additional pressure on WuXi AppTec due to the resonance effect of capital outflows in the sector. However, as a global leader in CRO/CDMO, the company's resilience during the industry's order recovery cycle is still viewed positively by some institutions

Technical Forecast

WUXI BIO

AKESO

WuXi Biologics

Pre-market trend | WuXi AppTec (2359.HK) shows bullish signals amid a significant pullback on 4/29. Can it stabilize and rebound?

603259

159837

159992

520880

159506

159316

Goldman Sachs analyst Ziyi Chen has assigned a Buy rating to WuXi AppTec Co., Ltd. Class H (2359) with a price target of HK$169.40. The stock closed at HK$143.10. Chen, who focuses on the Healthcare sector, has an average return of 2.8% and a 45.68% success rate on recommendations. The analyst consensus for WuXi AppTec is Strong Buy, with a price target consensus of HK$157.63.

Tip Ranks

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

Goldman Sachs

LIVZON PHARMA

LIVZON GROUP

3SBIO

Legend Biotech

GS Hldg R

Sunshine Guojian Pharmaceutical

WuXi AppTec Co., Ltd. Class H (2359) Receives a Buy from Goldman Sachs

G Sachs has raised its target price for WUXI APPTECto HKD169.4, maintaining a Buy rating. The company reported strong Q1 results, with a 25% increase in new orders and a 29% rise in backlog, driven by growth across all major business segments. Non-IFRS earnings forecasts for 2026-2028 were increased by 7% to 7.6%. Management plans to review guidance in Q2, while the small molecule CDMO business continues to show solid growth.

G Sachs Raises WUXI APPTEC  TP to HKD169.4, Business Growth Shows Resilience

Reuters

Penghua CSI HK Connect Health Care Composite ETF

Hang Seng Index

BUZZ-WuXi AppTec's Hong Kong shares climb to over four-year high on robust quarterly results

01888

01898

02714

06288

02513

03750

09660

01378

02333

WUXI APPTEC(02359) rose 13.57%, with a trading turnover 3.0 Billion HKD, and a year-to-date rose 45%. KB LAMINATES(01888) rose 7.35%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 170.1%. KNOWLEDGE ATLAS(02513) fell 12.52%, with a trading turnover 2.1 Billion HKD, and a year-to-date rose 588.5%. CATL(03750) fell 6.88%, with a trading turnover 9.3 Billion HKD, and a year-to-date rose 26.4%.

Top Gainers&Losers

KB LAMINATES

CHINA COAL

MUYUAN

FAST RETAIL-DRS

KNOWLEDGE ATLAS

CATL

HORIZONROBOT-W

CHINAHONGQIAO

GWMOTOR

Top 5 HK Stock Gainers/Losers (>100B) (4.28)

01528

06127

09959

01907

00326

02652

01277

WUXI APPTEC(02359) rose 13.57%, with a trading turnover 3.0 Billion HKD, and a year-to-date rose 45%. RS MACALLINE(01528) rose 11.11%, with a trading turnover 129.4 Million HKD, and a year-to-date rose 23%. JOINN(06127) rose 9.26%, with a trading turnover 216.2 Million HKD, and a year-to-date rose 14.6%.

RS MACALLINE

JOINN

LINKLOGIS-W

CHINA RISUN GP

CHINA STAR ENT

CF PHARMTECH

KINETIC DEV

Top 10 HK Stock Gainers (4.28)

WuXi AppTec rose 13.57%; WuXi Biologics rose 1.56%, with a transaction volume of HKD 1.017 billion; WuXi AppTec rose 2.33%, with a transaction volume of HKD 271 million; Kanglong Chemical rose 5.73%, with a transaction volume of HKD 226 million; Tigermed rose 3.54%, with a market value of HKD 37.8 billion

HK Stock Alerts

Hong Kong Stock Movement: WuXi AppTec's performance exceeded expectations, with a stock price increase of 13.57%! Investment banks are raising ratings, and market enthusiasm is high

WuXi AppTec's shares surged over 17% following strong first-quarter earnings, with Hong Kong-listed stock reaching 148.00 HKD. The company's net profit rose 27% to 4.65 billion yuan, and revenue increased 29% to 12.44 billion yuan, driven by higher clinical and commercial projects. Analysts view the results positively, suggesting they may lead to improved growth guidance. The Shanghai-listed stock also saw a 10% rise, marking its largest gain since October 2024.

MorningStar

WuXi AppTec Shares Rise After Strong First-Quarter Earnings

G Sachs reported that WuXi AppTecexceeded expectations in its 1Q26 results, with revenue rising 28.8% YoY to RMB12.44 billion. The growth was driven by a 43.7% increase in WuXi Chemistry and 27.4% in WuXi Testing. G Sachs maintains a Buy rating, setting a target price of HKD149.7 for H shares and RMB137.3 for A shares, citing strong earnings outlook and growth prospects. The stock is included on the Conviction List, supported by a solid order backlog and expanding capacity in key business areas.

G Sachs: WuXi AppTec  1Q26 Results Far Exceed Expectations; Maintains Buy Rating

JP-WXAT@EC2611A(28830.HK)

HSBC Research Raises WUXI APPTEC TP to HKD162.5, Maintains Buy